Alvotech Extends its Collaboration with Advanz Pharma to Commercialize Five Proposed Biosimilars in EU
- Advanz Pharma gets an exclusive right from Alvotech to commercialize five proposed biosimilars in the EU. Alvotech will be responsible for the development and commercial supply
- Advanz Pharma will leverage its existing specialty and hospital capabilities in the EU to ensure successful market registration, commercialization, and patient access. The agreement strengthens Advanz’s pipeline of specialty pharmaceuticals to drive mid- and long-term sustainable growth
- The agreement also incl. proposed biosimilars to Simponi, Entyvio & 3 additional early-stage undisclosed biosimilar candidates. Alvotech & Advanz Pharma collaborated in Feb 2023 to commercialize AVT23, a proposed biosimilar to Xolair (omalizumab)
Ref: Globenewswire | Image: Alvotech
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.